A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes

Inclusion Criteria:

- Patients with histologically confirmed advanced cervical cancer (squamous cell
carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): International
Federation of Gynecology and Obstetrics (FIGO) clinical stages IB2/IIA with positive
para-aortic lymph nodes or FIGO clinical stages IIB/IIIB/ IVA with positive pelvic
and/or para-aortic lymph nodes; nodal status will be confirmed by PET/CT scan, fine
needle biopsy, extra peritoneal biopsy, laparoscopic biopsy or lymphadenectomy

- Patients must have a Gynecologic Oncology Group (GOG) performance status of 0-1

- Absolute neutrophil count (ANC) >= 1,500/mcl

- Platelets >= 100,000/mcl

- Creatinine =< institutional upper limit normal (ULN); note: if creatinine > ULN,
creatinine clearance must be > 50 mL/min

- Bilirubin =< 1.5 x ULN

- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and
alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x
ULN

- Alkaline phosphatase =< 2.5 x ULN

- Neuropathy (sensory and motor) =< grade 1

- Patients with ureteral obstruction (i.e., hydronephrosis identified on CT imaging)
must undergo stent or nephrostomy tube placement prior to study entry

- Patients must meet the pre-entry requirements specified

- Patients must have signed an approved informed consent and authorization permitting
the release of personal health information

- Patients of child-bearing potential must have a negative serum pregnancy test prior
to study entry (within 72 hours prior to initiation of study treatment) and be
practicing an effective form of contraception; women should not breast-feed while on
this study

- Patients must not be receiving any other investigational agent

- Patients should have an audiogram at baseline, and patients with pre-existing hearing
loss or hearing loss during treatment should be assessed frequently during cisplatin
therapy

Exclusion Criteria:

- Patients who have received previous pelvic or abdominal radiation, cytotoxic
chemotherapy, or previous therapy of any kind for this malignancy or any pelvic or
abdominal radiation for any prior malignancy

- Patients with active infection

- Patients who have circumstances that will not permit completion of this study or the
required follow-up

- Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal
transplantation, that would require modification of radiation fields

- Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer, are excluded if there is any evidence of other malignancy
being present within the last five years; patients are also excluded if their
previous cancer treatment prevents full delivery of this protocol therapy

- Patients who have undergone major surgery, excluding diagnostic biopsy, within 30
days (to allow for full recovery) prior to registration

- Patients who have a significant history of cardiac disease, i.e., uncontrolled
hypertension, unstable angina, congestive heart failure, or uncontrolled arrhythmias
within 6 months of registration

- Patients with a history of prior treatment with ipilimumab, anti-PD 1 antibody, CD137
agonist or other immune activating therapy such as anti-CD 40 antibody

- Patients who are receiving any other investigational agents

- Autoimmune disease: patients with a history of inflammatory bowel disease, including
ulcerative colitis and Crohn's disease, are excluded from this study, as are patients
with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic
progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune
vasculitis [e.g., Wegener's Granulomatosis]); central nervous system (CNS) or motor
neuropathy considered of autoimmune origin (e.g. Guillain-Barre syndrome and
Myasthenia Gravis, multiple sclerosis)

- Patients with known immune impairment who may be unable to respond to anti-cytotoxic
T-lymphocyte-associated protein 4 (CTLA 4) antibody

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition ipilimumab or other agents used in study

- Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C
infections should be excluded